Behind the Scenes: Sources of Complementarity in R&D

Even though management consultants increasingly recommend that in-house research be outsourced, little is known about the conditions favoring substitution or complementarity between internal R&D and external technology acquisition. In this paper, we attempt to provide a deeper understanding of the firm-level drivers of complementarity between these two types of investments through the structural estimation of a flexible innovation production function, such as the translog. Our empirical analysis is based on a unique panel dataset on the R&D and in-licensing expenditures of 94 global pharmaceutical firms active in drug development between 1997 and 2005. Our results suggest that internal R&D and in-licensing in the pharmaceutical industry were neither complements nor substitutes during the study period. However, we find that the degree of complementarity is enhanced for firms with stronger absorptive capacity, economies of scope, and past licensing experience.

[1]  Ivan P. L. Png.  Law and Innovation: Evidence from State Trade Secrets Laws , 2012 .

[2]  Ignacio Fernández-de-Lucio,et al.  Does external knowledge sourcing matter for innovation? Evidence from the Spanish manufacturing industry , 2009 .

[3]  A. Arora,et al.  Evaluating technological information and utilizing it: Scientific knowledge, technological capability, and external linkages in biotechnology , 1994 .

[4]  A. Arora,et al.  The changing technology of technological change: general and abstract knowledge and the division of , 1994 .

[5]  Frank T. Rothaermel,et al.  Leveraging internal and external experience: exploration, exploitation, and R&D project performance , 2010 .

[6]  M J Myers,et al.  Pharmaceutical innovation. , 1966, American journal of pharmacy and the sciences supporting public health.

[7]  Franco Malerba,et al.  Knowledge, innovative activities and industrial evolution , 2000 .

[8]  A. Arora,et al.  Ideas for rent: an overview of markets for technology , 2010 .

[9]  CassimanBruno,et al.  In Search of Complementarity in Innovation Strategy , 2006 .

[10]  G. Pisano.  The R&D Boundaries of the Firm: An Empirical Analysis , 1990 .

[11]  Julian Lowe,et al.  R&D and technology purchase through licence agreements: complementary strategies and complementary assets , 1998 .

[12]  A. Arora,et al.  Markets for Technology: The Economics of Innovation and Corporate Strategy , 2002 .

[13]  Ashish Arora,et al.  A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development , 2009, Manag. Sci..

[14]  R. Willig,et al.  Economies of scope , 1981 .

[15]  Jiann-Chyuan Wang,et al.  External technology acquisition and firm performance: A longitudinal study , 2008 .

[16]  D. Teece.  Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[17]  Rebecca Henderson,et al.  Scale, Scope and Spillovers: The Determinants of Research Productivity in Ethical Drug Discovery , 2015 .

[18]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[19]  A. Arora,et al.  COMPLEMENTARITY AND EXTERNAL LINKAGES: THE STRATEGIES OF THE LARGE FIRMS IN BIOTECHNOLOGY* , 1990 .

[20]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[21]  Robin C. Sickles,et al.  The CES-Translog: Specification and Estimation of a New Cost Function , 1984 .

[22]  Daniel A. Levinthal,et al.  Innovation and Learning: The Two Faces of R&D , 1989 .

[23]  Bronwyn H. Hall,et al.  Industrial Research During the 1980s: Did the Rate of Return Fall? , 1993 .

[24]  Chung-ki Min,et al.  The substitution of information technology for other factors of production: a Firm Level Analysis , 1997 .

[25]  Paul R. Milgrom,et al.  The Economics of Modern Manufacturing: Technology, Strategy, and Organization , 1990 .

[26]  X. Vives.  Innovation and Competitive Pressure , 2004 .

[27]  Lloyd A. Jobe,et al.  Balancing vertical integration and strategic outsourcing: effects on product portfolio, product success, and firm performance , 2006 .

[28]  Jack A. Nickerson,et al.  Strategic Management of R&D Pipelines with Cospecialized Investments and Technology Markets , 2007, Manag. Sci..

[29]  Matthew J. Higgins,et al.  The outsourcing of R&D through acquisitions in the pharmaceutical industry , 2006 .

[30]  A. Arora,et al.  Markets for Technology: The Economics of Innovation and Corporate Strategy , 2004 .

[31]  Jaider Vega Jurado,et al.  Does external knowledge sourcing matter for innovation? Evidence from the Spanish manufacturing industry , 2009 .

[32]  H. Grabowski.  Patents, Innovation and Access to New Pharmaceuticals , 2002 .

[33]  Reinhilde Veugelers,et al.  In Search of Complementarity in Innovation Strategy: Internal R&D and External Knowledge Acquisition , 2006, Manag. Sci..

[34]  A. Salter,et al.  Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms , 2006 .

[35]  Daron Acemoglu,et al.  Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .

[36]  Maurizio Zollo,et al.  Deliberate Learning and the Evolution of Dynamic Capabilities , 2002 .

[37]  J. Hicks.  Marginal Productivity and the Principle of Variation , 1932 .

[38]  Avi Goldfarb,et al.  Understanding the Inputs into Innovation: Do Cities Substitute for Internal Firm Resources? , 2007, SSRN Electronic Journal.

[39]  Yves Morieux,et al.  Identifying R&D outliers , 2011, Nature Reviews Drug Discovery.

[40]  P. Danzon,et al.  Mergers and Acquisitions in the Pharmaceutical and Biotech Industries , 2004 .

[41]  T. Bresnahan,et al.  The Division of Inventive Labor and The Extent of The Market , 1997 .

[42]  J. DiMasi,et al.  Competitiveness in follow-on drug R&D: a race or imitation? , 2011, Nature Reviews Drug Discovery.

[43]  Edward,et al.  Measuring Trust , 2000 .

[44]  Ilan Guedj.  Ownership vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D , 2005 .

[45]  Andrea Fosfuri,et al.  The Penguin Has Entered the Building: The Commercialization of Open Source Software Products , 2008, Organ. Sci..

[46]  Laurits R. Christensen,et al.  The translog function and the substitution of equipment, structures, and labor in U.S. manufacturing 1929-68 , 1973 .

[47]  Ashish Arora,et al.  Patent Protection, Complementary Assets, and Firms' Incentives for Technology Licensing , 2004, Manag. Sci..

[48]  A. Arora,et al.  Licensing the market for technology , 2003 .

[49]  L. Bauwens,et al.  Econometrics , 2005 .